Turnover
≈ €110,000 estimated
The abbreviated format states no turnover.
NEUROPELT
Lifetime
2 annual accounts with figures on one time axispeak €45,163 (2024)
€37,241▼ 17.5%
peak €25,513 (2024)
€15,465▼ 39.4%
peak €46,977 (2025)
€46,977▲ 49.1%
€38,394▼ 24.0%
Board1 name since 2023
1 directorMEIJER Mariska
Documentsfilings and deeds
07-07-202624 days before the deadline
2025abbreviated format
Gross margin from €45,163 to €37,241Result from €25,513 to €15,465Equity from €31,513 to €46,977Debts from €50,519 to €38,394Cash from €5,748 to €17,692
Key points
from the 2025 annual accountsLiquidity
1.34 was 0.71 in 2024
Short-term debts fell from €30,611 to €25,955.
Position in the sector
€46,977
Less equity than 81% of companies in human health. Sector median €366,650 · 3,053 companies.
Checked score
94
Excellent
Financially stronger than 53% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,185 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.3%
01-2025: 0.3%● unchanged vs 12-2024
02-2025: 0.4%▲ +0.1 percentage points vs 01-2025
03-2025: 0.4%● unchanged vs 02-2025
04-2025: 0.4%● unchanged vs 03-2025
05-2025: 0.4%● unchanged vs 04-2025highest value
06-2025: 0.4%● unchanged vs 05-2025
07-2025: 0.4%● unchanged vs 06-2025
08-2025: 0.1%▼ -0.3 percentage points vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.2%▲ +0.1 percentage points vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.2%● unchanged vs 06-2026
08-2026: < 0.1%▼ -0.2 percentage points vs 07-2026lowest value
09-2026: < 0.1%● unchanged vs 08-2026lowest value
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Founded in 2023
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 1.34, cash €17,692
Figures for financial year 2025 (filed on 07-07-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 44% of them on solvency, 42% on liquidity, 48% on profitability and 80% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 39,278 companies had the same profile as NEUROPELT has now. Each dot stands for 99 companies, two years later.
95.8%
were still trading
2.3%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of NEUROPELT itself is lower: < 0.1% within 12 months. It rests on far more data about NEUROPELT than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,278 companies, not a prediction for NEUROPELT. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €4,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.34 (0.71 in 2024), below the usual 1.5. Short-term debt is 30.4% and cash 20.7% of total assets. 45% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.
NBB · 2 filingsDeviation from the deadline
2025
24 days early
2024
3 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 2 accounts on average 14 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- VRIJSEN Kurt Peter Lieve Valentin founderdeed of 06-09-2023
- MEIJER Mariska founderdeed of 06-09-2023
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0805421682
Incorporation
Founders: VRIJSEN Kurt Peter Lieve Valentin and MEIJER Mariska · 100 shares · Appointment: MEIJER Mariska (director) · published on 06-09-2023 · Gazette deed
First establishment
Overwegstraat 19, Pelt
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| NEUROPELT Pelt | €85,371 | €37,241 | 55.0% | - |
| MyoZolder Heusden-Zolder | €79,139 | €37,744 | 47.0% | - |
| Lennert Plessers Oudsbergen | €95,055 | €35,393 | 94.7% | - |
| Kine VDB Heusden-Zolder | €91,736 | €40,963 | 89.1% | - |
| RERO Beringen | €94,968 | €40,036 | 80.8% | - |
| HD Physio Beringen | €87,050 | €40,735 | 90.1% | - |
| Physio Motion SRL Ecaussinnes | €86,120 | €36,173 | 80.2% | - |
These companies have the same main activity as NEUROPELT: physiotherapy (NACE 86951). They are comparable in size and age: total assets between €79,100 and €95,100, founded in 2023.
Official details
Source: KBO- Status
- Active since 04-09-2023Normal situation
- Activity
- PhysiotherapyNACE 86951and 1 other
- Establishment unit
- 2.349.529.4463910 Pelt, since 04-09-2023
- Financial year end
- 31 December
- Peppol
- Reachable since 18-08-2026
Annual accounts 2025
- €85,371▲ 4.1%
- Filing
- Filed on 07-07-2026, 24 days before the end of the filing period
Insights on NEUROPELT
NEUROPELT has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €46,977 and a net result of €15,465.
Its solvency ranks better than 46% of 3,053 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about NEUROPELT
- What is the company number of NEUROPELT?
- The company number of NEUROPELT is 0805.421.682. The VAT number is the same number with BE in front: BE 0805.421.682.
- Where is NEUROPELT based?
- The registered office is at Overwegstraat 19, 3910 Pelt.Company details
- What does NEUROPELT do?
- According to the KBO register, the main activity is physiotherapy (NACE 86951).
- What is the legal form of NEUROPELT?
- NEUROPELT is a private limited company (BV).
- When was NEUROPELT founded?
- NEUROPELT was founded on 04-09-2023.
- Is NEUROPELT still active?
- Yes, NEUROPELT is an active enterprise in the KBO register.
- What is the turnover of NEUROPELT?
- The turnover in financial year 2025 is ≈ €110,000. This figure is estimated from the gross margin of €37,241 and 41 comparable companies (NACE 869). It probably lies between €80,000 and €140,000.Financials
- Is NEUROPELT profitable?
- In financial year 2025, NEUROPELT made a profit of €15,465.
- Where can I find the annual accounts of NEUROPELT?
- NEUROPELT filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of NEUROPELT due?
- NEUROPELT must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.